Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Research & Development: 2010-2024

Historic Research & Development for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $82.2 million.

  • Altimmune's Research & Development fell 24.46% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.8 million, marking a year-over-year decrease of 14.56%. This contributed to the annual value of $82.2 million for FY2024, which is 24.97% up from last year.
  • Latest data reveals that Altimmune reported Research & Development of $82.2 million as of FY2024, which was up 24.97% from $65.8 million recorded in FY2023.
  • In the past 5 years, Altimmune's Research & Development ranged from a high of $82.2 million in FY2024 and a low of $49.8 million during FY2020.
  • Its 3-year average for Research & Development is $72.9 million, with a median of $70.5 million in 2022.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 180.17% in 2020, then decreased by 6.72% in 2023.
  • Over the past 5 years, Altimmune's Research & Development (Yearly) stood at $49.8 million in 2020, then spiked by 49.76% to $74.5 million in 2021, then dropped by 5.37% to $70.5 million in 2022, then fell by 6.72% to $65.8 million in 2023, then rose by 24.97% to $82.2 million in 2024.